Tumor Marker relevant Publications: 2001-2007: A Semjonow

  1. De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A. Twenty Years of PSA: From Prostate Antigen to Tumor Marker. Rev Urol 2007; 9(3):113-23.

  2. Ronquist KG, Carlsson L, Ronquist G, Semjonow A, Wülfing C, Larsson A. Serum antibodies against prostasomal clusterin in prostate cancer patients. Scand J Clin Lab Invest 2007 Oct 9:1-12 [Epub ahead of print]

  3. Semjonow A. DiaPat-Test für die Prostatakarzinomdiagnostik. Urologe A 2007; 46(10):1428. Letter. German. No abstract available.

  4. Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C, Weiss G. Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. J Urol 2007; 177(5):1753-8. 

  5. Chandolia RK, Luetjens CM, Wistuba J, Semjonow A, Pühse G, Nieschlag E. Blockage of urine by intravesical ejaculate in cynomolgus monkeys. J Med Primatol 2007; 36(1):21-4.

  6. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis EP, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman UH, Jung K, Meyer HA. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. World J Urol 2007; 25(1):95-103. Epub 2007 Feb 28. 

  7. Bettendorf O, Oberpenning F, Kopke T, Heinecke A, Hertle L, Boecker W, Semjonow A. Implementation of a map in radical prostatectomy specimen allows visual estimation of tumor volume. Eur J Surg Oncol 2007; 33(3):352-7. Epub 2006 Dec 15. 
  8. Stephan C, Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples-a response to AW Roddam et al., Ann Clin Biochem 2006; 43: 35-48. Ann Clin Biochem. 2006; 43(Pt 5):421-2; author reply 422-3. No abstract available.
  9. Schmidt H, DeAngelis G, Eltze E, Gockel I, Semjonow A, Brandt B. Asynchronous growth of prostate cancer is reflected by circulating tumor cells delivered from distinct, even small foci, harboring loss of heterozygosity of the PTEN gene. Cancer Res 2006; 66(18):8959-65. 
  10. Börgermann C, Sieverding M, Fornara P, Graefen M, Hammerer P, Semjonow A, Schröder F, Rübben H. Urologe A 2006; 45(Supplement 04):127-133. German.
  11. Larsson A, Ronquist G, Wulfing C, Eltze E, Bettendorf O, Carlsson L, Nilsson BO, Semjonow A. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 2006; 24(3):195-200. 
  12. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA, Jung K. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J UroL 2005; 174(6):2150-3. 
  13. Soletermos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W, Bialk P, Gion M, Junker F, Schmid HP, Van Poppel H. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51(8):1342-51.
  14. Wülfing C, Eltze E, Yamini J, Wulfing P, Bierer S, Bocker W, Hertle L, Semjonow A, Sievert KD. Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 2005; 47(5):593-600. 
  15. Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Jung K. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. Clin Chem 2005; 51(3):532-9. 
  16. Bettendorf O, Schmidt H, Eltze E, Gockel I, Semjonow A, Burger H, Bocker W, Brandt B. Cytogenetic changes and loss of heterozygosity in atypical adenomatous hyperplasia, in carcinoma of the prostate and in non-neoplastic prostate tissue using comparative genomic hybridization and multiplex-PCR. Int J Oncol 2005; 26(1):267-74. 
  17. Schmidt H, De Angelis G, Bettendorf O, Eltze E, Semjonow A, Knichwitz G, Brandt B. Frequent detection and immunophenotyping of prostate-derived cell clusters in the peripheral blood of prostate cancer patients. Int J Biol Markers 2004; 19(2):93-9. 
  18. Jung K, Lein M, Stephan C, Von Hosslin K, Semjonow A, Sinha P, Loening SA, Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004 ; 111(5):783-91. 
  19. Jung K, Stephan C, Semjonow A, Lein M, Schnorr D, Loening SA. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 2003; 170(6 Pt 1):2302-5. 
  20. Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA, Jung K. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003; 170(4 Pt 1):1175-9. 
  21. Schmid HP, Prikler L, Semjonow A. Problems with prostate-specific antigen screening: a critical review. Recent Results Cancer Res 2003; 163:226-31; discussion 264-6. Review. 
  22.  Luboldt HJ, Peck KD, Oberpenning F, Schmid HP, Semjonow A. Bicycle riding has no important impact on total and free prostate-specific antigen serum levels in older men. Urology 2003; 61(6):1177-80. 
  23. Wesseling S, Stephan C, Semjonow A, Lein M, Brux B, Sinha P, Loening SA, Jung K. Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. Clin Chem 2003; 49(6 Pt 1):887-94.
  24. Oberpenning F, Hetzel S, Weining C, Brandt B, De Angelis G, Heinecke A, Lein M, Fornara P, Schmid HP, Hertle L, Semjonow A. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer? Eur Urol 2003; 43(5):478-84. 
  25. Bettendorf O, Heine B, Kneif S, Eltze E, Semjonow A, Herbst H, Stein H, Bocker W, Poremba C. Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer. Prostate 2003; 55(2):99-104. 
  26. Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer. Clin Chem Lab Med 2003; 41(1):90-4. 
  27. Oberpenning F, Weining C, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP, Semjonow A. Combining free and total prostate specific antigen assays from different manufacturers: the pitfalls. Eur Urol 2002; 42(6):577-82; discussion 582. 
  28. Oberpenning F, Schmid HP, Fuchs-Surdel W, Hertle L, Semjonow A. The impact of intraoperative manipulation of the prostate on total and free prostate-specific antigen. Int J Biol Markers 2002; 17(3):154-60. 
  29. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, Sinha P, Loening SA, Jung K. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002; 48(8):1279-87. 
  30. Semjonow A, Schmid HP. The rise and fall of PSA: clinical implications of prostate specific antigen kinetics. Urol Res 2002; 30(2):85-8. Review. No abstract available. 
  31. Semjonow A, Oberpenning F, Weining C, Schon M, Brandt B, De Angelis G, Heinecke A, Hamm M, Stieber P, Hertle L, Schmid HP. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer? Clin Chem 2001; 47(8):1472-5. No abstract available. 
  32. Nap M, Brockhoff G, Brandt B, Knuechel R, Leers MP, Schmidt H, De Angelis G, Eltze E, Semjonow A. Flow cytometric DNA and phenotype analysis in pathology. A meeting report of a symposium at the annual conference of the German Society of Pathology, Kiel, Germany, 6-9 June 2000. Virchows Arch 2001; 438(5):425-32. 
  33. Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Prostate 2001; 47(2):77-84.